Camurus Future Growth

Future criteria checks 6/6

Camurus is forecast to grow earnings and revenue by 49.2% and 25.1% per annum respectively. EPS is expected to grow by 50.1% per annum. Return on equity is forecast to be 55.3% in 3 years.

Key information

49.2%

Earnings growth rate

50.1%

EPS growth rate

Pharmaceuticals earnings growth	15.4%
Revenue growth rate	25.1%
Future return on equity	55.3%
Analyst coverage	Good
Last updated	03 May 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0RD1 - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4,375	1,794	2,120	2,139	3
12/31/2025	2,916	940	1,017	1,031	6
12/31/2024	1,875	297	245	263	6
12/31/2023	1,717	431	597	607	N/A
9/30/2023	1,610	460	614	622	N/A
6/30/2023	1,468	408	191	190	N/A
3/31/2023	1,020	115	138	133	N/A
12/31/2022	956	56	107	101	N/A
9/30/2022	871	28	21	18	N/A
6/30/2022	784	-13	-44	-39	N/A
3/31/2022	695	-69	-96	-90	N/A
12/31/2021	601	-90	-148	-143	N/A
9/30/2021	523	-142	-182	-179	N/A
6/30/2021	470	-156	-212	-209	N/A
3/31/2021	413	-128	-237	-234	N/A
12/31/2020	336	-167	-242	-239	N/A
9/30/2020	265	-174	-283	-270	N/A
6/30/2020	205	-216	-339	-324	N/A
3/31/2020	136	-284	-401	-380	N/A
12/31/2019	106	-290	-430	-404	N/A
9/30/2019	78	-305	-397	-381	N/A
6/30/2019	58	-286	-382	-367	N/A
3/31/2019	53	-266	-326	-317	N/A
12/31/2018	49	-235	-279	-274	N/A
9/30/2018	47	-200	-252	-249	N/A
6/30/2018	40	-208	-221	-218	N/A
3/31/2018	52	-187	-208	-207	N/A
12/31/2017	54	-191	-205	-203	N/A
9/30/2017	86	-166	N/A	-156	N/A
6/30/2017	104	-127	N/A	-142	N/A
3/31/2017	111	-102	N/A	-107	N/A
12/31/2016	114	-81	N/A	-208	N/A
9/30/2016	113	-85	N/A	-161	N/A
6/30/2016	120	-95	N/A	-155	N/A
3/31/2016	116	-189	N/A	-109	N/A
12/31/2015	155	-160	N/A	-6	N/A
9/30/2015	263	-53	N/A	101	N/A
12/31/2014	208	48	N/A	69	N/A
12/31/2013	198	99	N/A	163	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0RD1's forecast earnings growth (49.2% per year) is above the savings rate (1.8%).

Earnings vs Market: 0RD1's earnings (49.2% per year) are forecast to grow faster than the UK market (12.6% per year).

High Growth Earnings: 0RD1's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 0RD1's revenue (25.1% per year) is forecast to grow faster than the UK market (3.4% per year).

High Growth Revenue: 0RD1's revenue (25.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0RD1's Return on Equity is forecast to be very high in 3 years time (55.3%).

Camurus Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Recent updates

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings released: EPS: kr7.78 (vs kr1.01 in FY 2022)

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Full year 2023 earnings released: EPS: kr7.78 (vs kr1.01 in FY 2022)

Investor sentiment deteriorates as stock falls 17%

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

New minor risk - Shareholder dilution

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings released: EPS: kr1.56 (vs kr0.63 in 3Q 2022)

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: kr5.44 (vs kr0.15 in 2Q 2022)

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

First quarter 2023 earnings released: EPS: kr1.06 (vs kr0.014 loss in 1Q 2022)

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

Full year 2022 earnings released: EPS: kr1.01 (vs kr1.66 loss in FY 2021)

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings released: EPS: kr0.15 (vs kr0.89 loss in 2Q 2021)

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

First quarter 2022 earnings released: kr0.01 loss per share (vs kr0.40 loss in 1Q 2021)

Camurus AB (Publ) Elects Stefan Persson as New Board Member

Full year 2021 earnings released: kr1.66 loss per share (vs kr3.18 loss in FY 2020)

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Camurus Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Pants with Genetic Obesity Disoisorder

Forecast breakeven date pushed back to 2022

Camurus AB Announces Braeburn Receives New Complete Response Letter for Brixadi in the US

Insider recently sold kr392k worth of stock

The European Medicines Agency Accepts Camurus's Application to Extend the Buvidal Indication to Include Treatment of Chronic Pain

Independent Chairman recently bought kr852k worth of stock

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.38 loss in 3Q 2020)

Forecast to breakeven in 2021

Camurus AB (Publ) Announces FDA Grants Orphan Drug Designation in the US for CAM2029 for the Treatment of Polycystic Liver Disease

Independent Director recently bought kr79k worth of stock

Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.39 loss in 2Q 2020)

Camurus AB (Publ) Provides Earnings Guidance for the Year 2021

Camurus AB Announces Braeburn Resubmits New Drug Application for Brixadi in the US

Insider recently sold kr1.9m worth of stock

Camurus Announces Publication Superior Patient Treatment Satisfaction with Buvidal® Weekly and Monthly Depot Injections in Opioid Dependence

First quarter 2021 earnings released: kr0.40 loss per share (vs kr1.19 loss in 1Q 2020)

Camurus Re-Affirms Financial Outlook for 2021

The Australian TGA Approves Key Label Updates to Camurus AB (publ)'s Buvidal® for Treatment of Opioid Dependence

Full year 2020 earnings released: kr3.18 loss per share (vs kr6.23 loss in FY 2019)

New 90-day high: kr220

Full year 2020 earnings released: kr3.12 loss per share (vs kr6.23 loss in FY 2019)

Revenue misses expectations

New 90-day high: kr211

Insider recently sold kr1.8m worth of stock

Camurus AB Announces Management Changes

Camurus AB (publ) Announces Swissmedic Approves Buvidal for the Treatment of Opioid Dependence